Calcium carbonate as a phosphate binder in hemodialysis patients

DOI

Bibliographic Information

Other Title
  • 血液透析患者におけるリン吸着剤としての炭酸カルシウム
  • Assessment of its efficacy and limitation from the nursing standpoint
  • その効果と問題点の看護面からの検討

Search this article

Description

We evaluated, from the nursing standpoint, the effectiveness and limitations of calcium carbonate as a phosphate binder in 25 patients receiving hemodialysis.<br>Oral aluminum hydroxide gel was discontinued, and the same dose of calcium carbonate was substitued at the start. The dosage of calcium carbonate and 1α (OH) D3 were adjusted accordingly, aming to keep serum Ca below 11.0mg/dl and serum phosphorus below 7.0mg/dl. Five patients dropped out of the study, 2 because of gastrointestinal distress, and 3 because of hyperphosphatemia. After 12 months on this regimen, the serum aluminum concentration in 20 patients whose hyperphosphatemia was controlled with calcium carbonate alone had fallen significantly from 92.4±43.1 to 34.3±10.5μg/l (p<0.01). Tansient hypercalcemia. (>10.8mg/dl) was observed in ten of the 20 patients. At the final obsevation, mean serum Ca, phosphorus and AI-p were unchanged, while serum PTH increased significantly (p<0.05).<br>About half of the patients complained that it was more difficult to take cailcium carbonate than aluminum hydroxide gel, because the former was in powder form.<br>After dietary phosphate reistriction, the serum phosphate level in 3 patients showing hyperphosphatemia decreased and aluminum hydroxide gel was stopped.<br>We considered education about low phophate diet necessary in patients with hyperphosphatemia undergoing calcium carbonate therapy.

Journal

Keywords

Details 詳細情報について

  • CRID
    1390282679651448704
  • NII Article ID
    130003720848
  • DOI
    10.4009/jsdt1985.22.185
  • ISSN
    18846211
    09115889
  • Text Lang
    ja
  • Data Source
    • JaLC
    • Crossref
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top